Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 193

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 193
---
 Gaza Strip and conducted a series of attacks on civilian and
military targets. Following the attack, Israel’s security cabinet declared war against Hamas and commenced a military campaign
against Hamas and other terrorist organizations in parallel to their continued rocket and terror attacks. In addition, Hezbollah have
attacked military and civilian targets in Northern Israel, to which Israel has responded, including through increased air and ground
operations in Lebanon. Since the war broke out, our subsidiary’s operations have not been adversely affected by this situation,
and we have not experienced disruptions to our development activities. However, the intensity and duration of Israel’s current
war against Hamas and Hezbollah is difficult to predict at this stage, as are such war’s economic implications on the Company’s
business and operations and on Israel’s economy in general.

On June 13,
2025, in light of continued nuclear threats and intelligence assessments indicating imminent attacks, Israel launched a pre-emptive strike
directly targeting military and nuclear infrastructure inside Iran aimed to disrupt Iran’s capacity to coordinate or launch further
hostilities against Israel, as well as disrupt its nuclear program. On June 25, 2025, a ceasefire between Israel and Iran took effect.
Nonetheless, hostilities between Israel and Iran may resume and further escalate, with both sides launching attacks against one another.
Company’s subsidiaries experienced disruptions to their work during such period. Since June 25, 2025, The Company’s subsidiaries
have been returning to full activity together with its local vendors and consultants. The Company doesn’t expect a material adverse
effect on its business.

The Company
continues to monitor its ongoing activities and will make adjustments in its business if needed, including updating any estimates or
judgments impacting its financial statements as appropriate.

NOTE 2 – SIGNIFICANT ACCOUNTING POLICIES

Following
the closing of the Share Exchange agreement with Lipovation on July 23, 2024, in accordance with ASC 810, Lipovation’s financial
statement are presented as the “Predecessor” for periods prior to the closing of the acquisition. Revium Rx, which includes
consolidation of Lipovation Ltd subsequent to the acquisition, is the “Successor” for periods after the closing of the Business
Combination. As a result of the application of the acquisition method of accounting in the Successor period, the financial statements
for the Successor period are presented on a full step-up basis as a result of the acquisition and are therefore not comparable to the
financial statements of the Pre